32604-73-2

Basic information

• Product Name: 2-(2,3-Dihydro-benzo[1,4]dioxin-5-yloxy)-ethylamine
• Synonyms: 2-(2,3-Dihydro-benzo[1,4]dioxin-5-yloxy)-ethylamine
• CAS NO: 32604-73-2
• Molecular Formula: C₁₀H₁₃NO₃
• Molecular Weight: 195.21512
• Mol File: 32604-73-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 317.8°C at 760 mmHg
• Flash Point: 160.1°C
• Appearance: /
• Density: 1.201g/cm³
• Vapor Pressure: 0.000377mmHg at 25°C
• Refractive Index: 1.551
• CAS DataBase Reference: 2-(2,3-Dihydro-benzo[1,4]dioxin-5-yloxy)-ethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,3-Dihydro-benzo[1,4]dioxin-5-yloxy)-ethylamine(32604-73-2)
• EPA Substance Registry System: 2-(2,3-Dihydro-benzo[1,4]dioxin-5-yloxy)-ethylamine(32604-73-2)

Safety Data

• Hazardous Substances Data: 32604-73-2(Hazardous Substances Data)

Usage

Structure

A benzene ring fused to a 1,4-dioxin ring The compound has a specific structure that includes a benzene ring and a 1,4-dioxin ring.

Classification

Amine derivative with a dioxin structure The compound is classified as an amine derivative due to the presence of an ethylamine group.

Usage

Organic synthesis and pharmaceutical research This compound is commonly used in the development of potential drug candidates targeting various biological pathways.

Pharmacological activities

Antitumor, antimicrobial, and antiparasitic properties The compound has been shown to exhibit various pharmacological activities, including antitumor, antimicrobial, and antiparasitic properties.

Potential treatment

Neurological disorders and modulation of neurotransmitter systems The compound has been investigated for its potential role in the treatment of neurological disorders and its ability to modulate neurotransmitter systems in the brain.

Further research

Needed to fully understand its medicinal potential and safety profile Further research is required to fully understand the medicinal potential and safety profile of this compound.

InChI:InChI=1/C10H13NO3/c11-4-5-12-8-2-1-3-9-10(8)14-7-6-13-9/h1-3H,4-7,11H2

Upstream product

• 1710-62-9 5-(2-bromoethoxy)-2,3-dihydrobenzo[b][1,4]dioxine 
• 87-66-1 2-hydroxyresorcinol 
• 10288-36-5 2,3-dihydro-1,4-benzodioxin-5-ol 
• 10288-38-7 5-(2-chloroethoxy)-2,3-dihydrobenzo[1,4]dioxine 
• 245762-30-5 2-(2,3-dihydrobenzo[1,4]dioxin-5-yloxy)ethyl azide 
• 214894-96-9 2-(2-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)oxy)ethyl)isoindoline-1,3-dione 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

Substituted oxygenated heterocycles and thio-analogues: Synthesis and biological evaluation as melatonin ligands

A new series of substituted oxygenated heterocycles and thio-analogues were synthesized and evaluated as melatonin receptor ligands. The replacement of the indolic moiety of melatonin by heterocyclic skeleton such as 1,4- benzodioxin, 2,3-dihydro-1,4-benzodioxin, chroman, 2,3-dihydro-1,4- benzoxathiin, thiochroman, carrying the amidic chain on the aromatic ring, leads to compounds showing a weak affinity for melatonin receptors, except for the compounds 1cb and 1hb. (C) 2000 Elsevier Science Ltd.